3/2
09:27 am
help
Cybin (HELP) had its price target raised by HC Wainwright from $55.00 to $95.00. They now have a "buy" rating on the stock.
Medium
Report
Cybin (HELP) had its price target raised by HC Wainwright from $55.00 to $95.00. They now have a "buy" rating on the stock.
2/27
12:12 pm
help
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments [Globe and Mail, The (Toronto, Canada)]
Low
Report
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments [Globe and Mail, The (Toronto, Canada)]
2/26
12:23 pm
help
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders [Globe and Mail, The (Toronto, Canada)]
Medium
Report
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders [Globe and Mail, The (Toronto, Canada)]
2/24
11:57 pm
help
HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience [Seeking Alpha]
Medium
Report
HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience [Seeking Alpha]
2/24
07:45 am
help
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee
Medium
Report
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee
2/18
09:53 pm
help
Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)'s Science-Driven Psilocybin Therapies as Key Growth Drivers [Yahoo! Finance]
Low
Report
Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)'s Science-Driven Psilocybin Therapies as Key Growth Drivers [Yahoo! Finance]
2/17
07:30 am
help
Nature Medicine Publishes Helus Pharma’s Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
Medium
Report
Nature Medicine Publishes Helus Pharma’s Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
2/13
07:31 am
help
HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
Low
Report
HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
2/13/2026
07:37 am
help
cybin inc.
MISS
Report
0.0%
cybin inc.
2/24
05:17 pm
help
Form 6-K CYBIN INC. For: Feb 24
Low
Report
Form 6-K CYBIN INC. For: Feb 24
2/18
01:56 pm
help
Form 6-K CYBIN INC. For: Feb 18
Low
Report
Form 6-K CYBIN INC. For: Feb 18
2/17
06:21 pm
help
Form SCHEDULE 13G CYBIN INC. Filed by: ORBIMED ADVISORS LLC
Low
Report
Form SCHEDULE 13G CYBIN INC. Filed by: ORBIMED ADVISORS LLC
2/17
05:26 pm
help
Form 6-K CYBIN INC. For: Feb 17
Medium
Report
Form 6-K CYBIN INC. For: Feb 17
2/17
04:16 pm
help
Form SCHEDULE 13G/A CYBIN INC. Filed by: TANG CAPITAL MANAGEMENT LLC
Medium
Report
Form SCHEDULE 13G/A CYBIN INC. Filed by: TANG CAPITAL MANAGEMENT LLC
2/13
08:47 am
help
Form SCHEDULE 13G/A CYBIN INC. Filed by: Deep Track Capital, LP
Low
Report
Form SCHEDULE 13G/A CYBIN INC. Filed by: Deep Track Capital, LP
2/13
07:38 am
help
Form 6-K CYBIN INC. For: Feb 13
Low
Report
Form 6-K CYBIN INC. For: Feb 13
2/10
05:10 pm
help
Form 6-K CYBIN INC. For: Feb 10
Low
Report
Form 6-K CYBIN INC. For: Feb 10
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd lot
Avg. bid-ask spread
Avg. bid-ask size
Shares at ask/bid
Off exchange
Main News & Impact Reports
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Register